Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool

BACKGROUND: Rare diseases are defined as life-threatening or chronically debilitating diseases with a prevalence of 50 out of 100,000 individuals or less. Orphan medicinal products (OMPs) are intended for the treatment of rare diseases. The assessment of quality of evidence in small populations is o...

Descripción completa

Detalles Bibliográficos
Autores principales: Picavet, Eline, Cassiman, David, Aertgeerts, Bert, Simoens, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856624/
https://www.ncbi.nlm.nih.gov/pubmed/24107467
http://dx.doi.org/10.1186/1750-1172-8-157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856624/
https://www.ncbi.nlm.nih.gov/pubmed/24107467
http://dx.doi.org/10.1186/1750-1172-8-157

Ejemplares similares